Joseph Keenan
Contributing Editor at Fierce Biotech
Contributing Editor at FiercePharma
Articles
-
3 days ago |
fiercepharma.com | Joseph Keenan
For a second time in less than a month, a new CDMO has uncloaked. This time, Meribel Pharma Solutions is gracing the stage after its financial backer snapped up a string of production facilities from Recipharm and acquired the French contract manufacturer Synerlab. Meribel, which will be based in the United Kingdom, is positioning itself as a mid-sized CDMO with a "strong legacy of expertise" in oral solid, semi-solid and sterile drugs, the company said in an April 15 press release.
-
1 week ago |
fiercepharma.com | Joseph Keenan
Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key regulatory hurdle at its flagship production plant in the United Kingdom. The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has granted Moderna a manufacturer and importer's license at its vaccine facility in Harwell, Oxfordshire.
-
1 week ago |
fiercepharma.com | Joseph Keenan
Aurobindo's manufacturing operations have once again landed the Indian drugmaker in hot water with the U.S. FDA. Aurobindo's subsidiary Aurolife Pharma received a Form 483 from the FDA outlining 11 observations at a U.S. production plant, the Indian drugmaker said in a filing late last week. The exact nature of the infractions remain unclear, as the FDA has not published the document.
-
2 weeks ago |
fiercepharma.com | Joseph Keenan
Looking to cement its spot in the burgeoning realm of radiopharmaceuticals, Florida-based contract manufacturer PharmaLogic is moving forward with a nuclear medicine M&A play. PharmaLogic is paying an undisclosed sum to pick up a majority stake in Norway’s Agilera Pharma. The move forms part of the CDMO’s strategy to position itself as the industry's first global contract manufacturer specifically dedicated to radiopharmaceuticals, PharmaLogic said in a press release.
-
2 weeks ago |
fiercepharma.com | Joseph Keenan
Shipping and logistics giant DHL Group is earmarking 2 billion euros ($2.2 billion) to bulk up its healthcare supply chain operations in order to meet growing demand from the biopharma industry. Half of the investment will target the Americas with the remaining half split between the Asia Pacific region and Europe, Middle East and Africa regions, the company said in an April 7 press release. The company plans to invest the total sum over the next 5 years.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →